Russia's R-Pharm to develop UCB's olokizumab for rheumatoid arthritis

4 July 2013

Belgium’s leading pharma company UCB (Euronext Brussels: UCB) said today (July 4) that it has granted a world-wide exclusive license to privately-owned R-Pharm, one of Russia's leading pharmaceutical producers, to develop and commercialize olokizumab in all indications, including rheumatoid arthritis.

Under the terms of this agreement, R-Pharm will develop, register, manufacture, distribute and book sales globally. UCB receives an upfront payment and is entitled to receive payments on development and commercialization milestones and royalties. Further details of the deal were not disclosed.

Roch Doliveux, UCB chief executive, said: "We at UCB are very satisfied with the positive Phase II results for olokizumab. Following the prioritization of UCB’s rich pipeline, we took the portfolio decision to partner olokizumab. We are pleased that R-Pharm will provide a potential new treatment option for patients with immunology diseases."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK